Agilon Health, Inc.
NYSE:AGLMedical - Care Facilities
+$2.26 today
- Market cap
- $1.52B
- Beta
- 3.04
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$22.50
Volume 0.79M
Average 0.41M
AGL Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Agilon Health, Inc.NYSE: AGL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $6.79M fell 1.3% year over year, behind the +11.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.6% from the prior quarter. Over 3 fiscal years it compounded at +27.6% a year.
Context
- Depreciation & amortization amounted to 0.5% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -1.3% toward the trailing-twelve-month pace of +11.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 28.59M USD
- Year-over-year change
- +16.9%
- 4-year CAGR
- +18.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.59M | +16.9% |
| FY2024 | 2024-12-31 | 24.46M | +21.3% |
| FY2023 | 2023-12-31 | 20.16M | +46.4% |
| FY2022 | 2022-12-31 | 13.77M | -6.1% |
| FY2021 | 2021-12-31 | 14.67M | — |
Depreciation & Amortization vs competitors
How AGL compares with its peers on the latest reported figures
- AGL's LTM Mar 2026 depreciation & amortization of $28.51M is the 2nd largest of the 10 companies compared; the peer median is $2.17M.
- Its year-over-year change of +11.8% is the 6th highest of 10, against a peer median of +13.0%.
- Depreciation & amortization amounts to 0.5% of revenue for AGL, versus a peer median of 12.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $55.54M | +5.2% | -0.5% | 23.3% | |
| LTM Mar 2026 | $28.51M | +11.8% | +27.6% | 0.5% | |
| LTM Mar 2026 | $9.98M | +13.0% | +19.6% | 12.3% | |
| LTM Feb 2026 | $6.47M | -19.3% | +32.0% | 8.0% | |
| LTM Mar 2026 | $3.14M | +14181.8% | -37.6% | — | |
| LTM Mar 2026 | $2.17M | +0.9% | +0.9% | — | |
| LTM Mar 2026 | $1.34M | +611.6% | +25.6% | 34.2% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $670K | +79.6% | +28.8% | — |
| LTM Mar 2026 | $326K | +176.0% | — | — | |
MCTACharming Medical Limited Class A Ordinary Shares | FY2024 | $263.45K | -32.7% | — | 4.2% |
| Peer median (excluding AGL) | $2.17M | +13.0% | +19.6% | 12.3% | |
Competitors are the stored peer set for AGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (406.79M) | (106.86M) | (262.8M) | (260.1M) | (391.35M) |
| Depreciation & Amortization | 14.67M | 13.77M | 20.16M | 24.46M | 28.59M |
| Deferred Income Tax | (3.23M) | 532K | 0 | 0 | 0 |
| Stock-Based Compensation | 292.39M | 28.38M | 69.33M | 50.66M | 49.12M |
| Change in Working Capital | (55.03M) | (59.44M) | (10.07M) | 130.59M | 189.47M |
| Accounts Receivables | (149.04M) | (204.17M) | 0 | (74.58M) | 344.59M |
| Inventory | 149.04M | 0 | 0 | 0 | 0 |
| Accounts Payables | 95.7M | 173.45M | 473.61M | 198.58M | (87.48M) |
| Other Working Capital | (150.72M) | (28.72M) | (483.68M) | 6.59M | (67.64M) |
| Other Non-Cash Items | 9.82M | (7.19M) | 27.18M | (3.39M) | 18.4M |
| Operating Cash Flow | (148.16M) | (130.81M) | (156.2M) | (57.78M) | (105.76M) |
| Capital Expenditures | (13.43M) | (32.66M) | (30.82M) | (13.25M) | (13.24M) |
| Acquisitions (Net) | (1.34M) | 500K | (43.06M) | 0 | 0 |
| Purchases of Investments | (7.1M) | (458.27M) | (114.66M) | (12.01M) | (60.15M) |
| Sales of Investments | 7.1M | 52.55M | 164.04M | 206.92M | 193.87M |
| Other Investing Activities | (75.74M) | (23.75M) | (34.51M) | (41.77M) | (31.87M) |
| Investing Cash Flow | (90.51M) | (444.39M) | (44.02M) | 139.89M | 88.61M |
| Debt Repayment | (19.9M) | (5M) | (5M) | (3.75M) | 0 |
| Common Stock Issued | 1.19B | 33.06M | 11.87M | 1.17M | 0 |
| Common Stock Repurchased | 0 | 0 | (200M) | 0 | (2.99M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (14.74M) | 0 | 11.87M | 0 | 0 |
| Financing Cash Flow | 1.15B | 28.06M | (193.13M) | (2.58M) | (2.99M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 915.73M | (547.14M) | (393.35M) | 79.53M | (20.15M) |
| Free Cash Flow | (161.59M) | (163.47M) | (187.01M) | (71.03M) | (119.01M) |
Agilon Health, Inc.
NYSE:AGL
Intrinsic Alpha fair value
Locked
Current Price
$90.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.